EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 34 / No 3 (Mars 2018) Med Sci (Paris), 34 3 (2018) 214-218 References
Free Access
Issue
Med Sci (Paris)
Volume 34, Number 3, Mars 2018
Page(s) 214 - 218
Section Le Magazine
DOI https://doi.org/10.1051/medsci/20183403008
Published online 16 March 2018
  1. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418 : 646-50. [CrossRef] [PubMed] [Google Scholar]
  2. Laguette N, Sobhian B, Casartelli N, et al. SAMHD1 is the dendritic-and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011; 474 : 654-7. [CrossRef] [PubMed] [Google Scholar]
  3. Haller O, Kochs G. Human MxA protein: an interferoninduced dynamin-like GTPase with broad antiviral activity. J Interferon Cytokine Res 2011; 31 : 79-87. [CrossRef] [PubMed] [Google Scholar]
  4. Matzinger SR, Carroll TD, Dutra JC, et al. Myxovirus resistance gene A (MxA) expression suppresses influenza A virus replication in alpha interferontreated primate cells. J Virol 2013; 87 : 1150-8. [CrossRef] [PubMed] [Google Scholar]
  5. Tartour K, Cimarelli A. Les IFITM, un obstacle commun à de nombreux virus Med Sci (Paris) 2015; 31 : 377-82. [Google Scholar]
  6. Compton AA, Bruel T, Porrot F, et al. IFITM proteins incorporated into HIV-1 virions impair viral fusion and spread. Cell Host Microbe 2014; 16 : 736-47. [CrossRef] [PubMed] [Google Scholar]
  7. Tartour K, Appourchaux R, Gaillard J, et al. IFITM proteins are incorporated onto HIV-1 virion particles and negatively imprint their infectivity. Retrovirology 2014; 11 : 103. [CrossRef] [PubMed] [Google Scholar]
  8. Yu J, Li M, Wilkins J, et al. IFITM proteins restrict HIV-1 infection by antagonizing the envelope glycoprotein. Cell Rep 2015; 13 : 145-56. [CrossRef] [PubMed] [Google Scholar]
  9. Wang Y, Pan Q, Ding S, et al. The V3 loop of HIV-1 Env determines viral susceptibility to IFITM3 impairment of viral infectivity. J Virol 2017; 91 : e02441-16. [PubMed] [Google Scholar]
  10. Tartour K, Nguyen XN, Appourchaux R, et al. Interference with the production of infectious viral particles and bimodal inhibition of replication are broadly conserved antiviral properties of IFITMs. PLoS Pathog 2017; 13 : e1006610. [CrossRef] [PubMed] [Google Scholar]
  11. Foster TL, Wilson H, Iyer SS, et al. Resistance of transmitted founder HIV-1 to IFITM-mediated restriction. Cell Host Microbe 2016; 20 : 429-42. [CrossRef] [PubMed] [Google Scholar]
  12. Wu WL, Grotefend CR, Tsai MT, et al. Delta20 IFITM2 differentially restricts X4 and R5 HIV-1. Proc Natl Acad Sci USA 2017; 114 : 7112-7. [CrossRef] [Google Scholar]
  13. Amini-Bavil-Olyaee S, Choi YJ, Lee JH, et al. The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. Cell Host Microbe 2013; 13 : 452-64. [CrossRef] [PubMed] [Google Scholar]
  14. Fu B, Wang L, Li S, Dorf ME. ZMPSTE24 defends against influenza and other pathogenic viruses. J Exp Med 2017; 214 : 919-29. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.